姜爭

寄語

患者朋友您好，我是中國醫(yī)學科學院腫瘤醫(yī)院結直腸外科姜爭醫(yī)生，我將在好大夫平臺秉承以下宗旨，幫助大家守衛(wèi)自身健康：
做一名用心看病的好醫(yī)生；
永遠以患者的利益為中心；
永遠從患者的角度看問題；

專業(yè)擅長

結腸癌、直腸癌等結直腸良惡性腫瘤的手術治療，尤其擅長超低位直腸癌保肛手術和腹部無輔助切口（NOSES）結直腸癌微創(chuàng)手術

個人簡介

姜爭，男，中共黨員，主任醫(yī)師，腫瘤學博士、博士后，碩士研究生導師，從事結直腸腫瘤外科臨床工作。2010年于復旦大學獲得腫瘤學博士學位；2010-2014年臨床醫(yī)學博士后流動站從事結直腸癌臨床及基礎研究；2014-2015年以訪問學者身份于美國德州大學MD Anderson癌癥中心從事腫瘤學研究?，F(xiàn)為中國醫(yī)學科學院腫瘤醫(yī)院主任醫(yī)師。英國皇家醫(yī)學會會員（FRSM）；美國癌癥研究協(xié)會（AACR）會員；美國臨床腫瘤協(xié)會（ASCO）會員；入選高校青年學術骨干支持計劃。擅長結直腸癌手術，手術視頻多次在國際大賽中獲得冠軍。

社會任職

國家癌癥中心國家腫瘤質控中心結直腸癌質控專委會秘書長中華醫(yī)學會第二屆中華腫瘤明日之星中國抗癌協(xié)會腫瘤轉移專委會委員中國抗癌協(xié)會整合腫瘤分會委員中國醫(yī)師協(xié)會整合腫瘤學專業(yè)委員會委員中國醫(yī)促會結直腸病學分會委員《中華結直腸疾病電子雜志》通訊編委、英文編輯《實用腫瘤學雜志》特約審稿專家《中華腫瘤防治雜志》編委《中國普通外科雜志》青年編委

獲獎榮譽

開創(chuàng)結腸癌、直腸癌治療新手術方式獲省級醫(yī)療衛(wèi)生新技術應用獎2次；中華醫(yī)學會第二屆中華腫瘤明日之星；入選高校青年學術骨干支持計劃

科研成果

主持國家、省級課題多項。主編人民衛(wèi)生電子音像出版社腹腔鏡手術教材5部，參編NOSES手術學專著3部，主譯Springer出版社出版英文版NOSES專著1部。發(fā)表SCI期刊收錄論文98余篇，其中第一/通訊作者身份發(fā)表30余篇，發(fā)表中文核心期刊30余篇。近年代表性文章：1.Short-term and oncological outcomes of natural orifice specimen extraction surgery (NOSES) for colorectal cancer in China: a national database study of 5055 patients. Science Bulletin 2022. 2.Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications. J Diabetes Res. 2022;2022:1747326.3.Association of Radiotherapy for Rectal Cancer and Second Gynecological Malignant Neoplasms. JAMA Netw Open. 2021;4:e2031661. 4.Deciphering the Pyroptosis-Related Prognostic Signature and Immune Cell Infiltration Characteristics of Colon Cancer. Front Genet. 2021;12:755384. 5.Integrative Analysis of Biomarkers Through Machine Learning Identifies Stemness Features in Colorectal Cancer. Front Cell Dev Biol. 2021;9:724860.6.LncRNA EGOT/miR-211-5p Affected Radiosensitivity of Rectal Cancer by Competitively Regulating ErbB4. Onco Targets Ther. 2021;14:2867-2878. 7.A prognostic index model to individually predict clinical outcomes for colorectal cancer with synchronous bone metastasis. J Cancer. 2020;11:4366-4372. 8.BMI May Be a Prognostic Factor for Local Advanced Rectal Cancer Patients Treated with Long-Term Neoadjuvant Chemoradiotherapy. Cancer Manag Res. 2020;12:10321-10332. 9.Leptin Overexpression as a Poor Prognostic Factor for Colorectal Cancer. Biomed Res Int. 2020;2020:7532514. 10.Prognostic scoring system for synchronous brain metastasis at diagnosis of colorectal cancer: A population-based study. World J Gastrointest Oncol. 2020;12:195-204. 11.Safety and Long-Term Effect Assessment of Neoadjuvant Chemoradiotherapy for Elderly Patients With Locally Advanced Rectal Cancer: A CHN Single-Center Retrospective Study. Technol Cancer Res Treat. 2020;19:1079237987. 12.The Distinction of Clinicopathological Characteristics, Treatment Strategy and Outcome in Colorectal Cancer Patients With Synchronous vs. Metachronous Bone Metastasis. Front Oncol. 2020;10:974.13.A Novel Method for Microsatellite Instability Detection by Liquid Biopsy Based on Next-Generation Sequencing. Current Bioinformatics 2020;15:1-10.14.Computational Identification of 29 Colon and Rectal Cancer-Associated Signatures and Their Applications in Constructing Cancer Classification and Prognostic Models. Front. Genet. 11:740. 15.MALAT1 sponges miR-106b-5p to promote the invasion and metastasis of colorectal cancer via SLAIN2 enhanced microtubules mobility. Ebiomedicine. 2019;41:286-298. 16.Abnormal Liver Function Induced by Space-Occupying Lesions Is Associated with Unfavorable Oncologic Outcome in Patients with Colorectal Cancer Liver Metastases. Biomed Res Int. 2018;2018:9321270.

工作經(jīng)歷

教育經(jīng)歷